BioSpace News Archive

Drug Development

PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, hosted a virtual Key Opinion Leader event discussing the significant unmet medical need in the prevention of surgical site infections.

June 18, 2024
·
7 min read
Lone Star Bio

Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect

Nanoscope Therapeutics Inc. today announced that management will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on June 25-26, 2024.

June 18, 2024
·
1 min read
Business

Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases

Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.

June 18, 2024
·
3 min read
BioCapital

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).

June 18, 2024
·
9 min read
Biotech Bay

Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases

Marea Therapeutics today with $190 million in combined Series A and B financings.

June 18, 2024
·
6 min read
Business

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team

PureTech Health plc today announced it has expanded its executive team with the appointment of Antony Loebel, M.D., as Chief Medical Officer and President of Clinical Development, and Lana Gladstein, J.D., as General Counsel.

June 18, 2024
·
10 min read
Business

Seaport Therapeutics Appoints Seasoned Executives to Management Team

Seaport Therapeutics today announced it has expanded its executive team with the appointment of Antony Loebel, M.D., as Chief Medical Officer and President of Clinical Development, and Lana Gladstein, J.D., as General Counsel.

June 18, 2024
·
5 min read
Drug Development

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. today announced positive topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

June 18, 2024
·
15 min read
BioMidwest

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

Orsini Specialty Pharmacy, and Zevra Therapeutics, Inc. announced that Orsini is now the pharmacy partner for OLPRUVA® for oral suspension.

June 18, 2024
·
7 min read
Drug Development

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

Spyre Therapeutics, Inc. today announced that it has initiated dosing of healthy volunteers in its first clinical trial of SPY001, an investigational novel half-life extended anti-α4β7 monoclonal antibody.

June 18, 2024
·
7 min read